Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 9, 1035-1043, September 2007; doi:10.1634/theoncologist.12-9-1035
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipton, A.
Right arrow Articles by Coleman, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipton, A.
Right arrow Articles by Coleman, R. E.

Breast Cancer

Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity

Allan Liptona, Richard J. Cookb, Pierre Majorc, Matthew R. Smithd, Robert E. Colemane

aMilton S. Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania, USA; bUniversity of Waterloo, Department of Statistics and Actuarial Science, Waterloo, Canada; cJuravinski Cancer Centre, Hamilton, Canada; dMassachusetts General Hospital Cancer Center, Boston, Massachusetts, USA; eUniversity of Sheffield, Weston Park Hospital, Cancer Research Centre, Sheffield, United Kingdom

Key Words. Biologic markers • Breast neoplasms • Survival rate • Zoledronic acid

Correspondence: Allan Lipton, M.D., Milton S. Hershey Medical Center, Penn State Cancer Institute, 500 University Drive, Hershey, Pennsylvania 17033, USA. Telephone: 717-531-5960; Fax: 717-531-5076; e-mail: alipton{at}psu.edu

Disclosure: R.J.C. has acted as a consultant to and performed contract work for Novartis Pharmaceuticals Corporation.P.M. has acted as a consultant to Novartis Oncology. M.R.S. has acted as a consultant to and has a financial interest in Novartis Oncology. R.E.C. has acted as a consultant to and has a financial interest in Novartis. A.L. has acted as a consultant to Novartis, Merck, Amgen, and GlaxoSmithKline, and he has a financial interest in Novartis, Amgen, and Pfizer.

Objective. Most breast cancer patients with bone metastases will receive bisphosphonate treatment. This post hoc analysis investigated whether early normalization of urinary N-telopeptide of type I collagen (NTX) levels during bisphosphonate therapy correlates with a long-term reduction in skeletal-related event (SRE) risk and mortality in patients with breast cancer.

Methods. This was a retrospective subset analysis of a phase III randomized trial comparing i.v. zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma. Patients with breast cancer who had NTX assessments at baseline and at months 1 and 3 (n = 342) were classified as normal (NTX <64 nmol/mmol creatinine) or elevated (NTX ≥64 nmol/mmol creatinine). The relative risk for an SRE or death was estimated with Cox regression models.

Results. Among the 328 evaluable patients treated with zoledronic acid, 196 patients (59.7%) had elevated baseline NTX, with 149 of those patients (76.0%) having normalized NTX levels and 31 patients (15.8%) having persistently elevated NTX levels at 3 months. The normalized NTX group had significantly lower risks for a first SRE, a first fracture or surgery to bone, or death than the group that had persistently elevated NTX levels.

Conclusions. These results suggest that early normalization of elevated baseline NTX while receiving zoledronic acid is associated with longer event-free and overall survival times compared with persistently elevated NTX. Further analyses in cancer patients with elevated marker levels are warranted to confirm the implications of these findings.




This article has been cited by other articles:


Home page
JBJSHome page
P. Zwolak, J. C. Manivel, P. Jasinski, M. N. Kirstein, A. Z. Dudek, J. Fisher, and E. Y. Cheng
Cytotoxic Effect of Zoledronic Acid-Loaded Bone Cement on Giant Cell Tumor, Multiple Myeloma, and Renal Cell Carcinoma Cell Lines
J. Bone Joint Surg. Am., January 1, 2010; 92(1): 162 - 168.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. E. Coleman, T. A. Guise, A. Lipton, G. D. Roodman, J. R. Berenson, J.-J. Body, B. F. Boyce, L. M. Calvi, P. Hadji, E. V. McCloskey, et al.
Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference
Clin. Cancer Res., October 15, 2008; 14(20): 6387 - 6395.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. D. Ottewell, B. Deux, H. Monkkonen, S. Cross, R. E. Coleman, P. Clezardin, and I. Holen
Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo
Clin. Cancer Res., July 15, 2008; 14(14): 4658 - 4666.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement